A U.S. appeals court has blocked the sale of Novartis AG’s Zarxio, a recently approved biosimilar form of Amgen Inc.’s cancer drug Neupogen, which is used to prevent infections in cancer patients undergoing chemotherapy.
On May 5, the U.S. Court of Appeals for the Federal Circuit in Washington granted Amgen’s request to block the sale of Zarxio while Amgen’s appeal of a lower-court ruling, which allowed the drug to go to market, is pending. The appeal case is scheduled to begin with oral arguments on June 3.
The U.S. Food and Drug Administration approved Zarxio in March.
Biosimilars are on the way, but who benefits?
FDA: Novartis does not have to share information with Amgen over new biosimilar drug